Merus - Stock Price History | MRUS

Historical daily share price chart and data for Merus since 2021 adjusted for splits. The latest closing stock price for Merus as of October 22, 2021 is 28.35.
  • The all-time high Merus stock closing price was 32.23 on March 06, 2017.
  • The Merus 52-week high stock price is 31.80, which is 12.2% above the current share price.
  • The Merus 52-week low stock price is 11.19, which is 60.5% below the current share price.
  • The average Merus stock price for the last 52 weeks is 21.26.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merus Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 14.4846 13.4800 19.4400 10.5000 17.5300 24.50%
2019 14.9040 14.3000 20.5200 11.0900 14.0800 0.57%
2018 18.1317 16.3900 26.3900 11.4600 14.0000 -27.84%
2017 19.3277 21.0700 32.2300 13.6000 19.4000 -8.10%
2016 12.3551 10.0400 21.3800 7.6200 21.1100 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.091B $0.030B
Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76